Carbidopa Articles
Drug candidates in pipeline offer potential for Parkinson's disease market, says Frost & Sullivan
9 December 2009
Impax updates on lead candidates
21 April 2009
Orion withdraws MAA for expanded Stalevo label
16 March 2009
Azilect helps "double 2nd-line MAO-Bs in PD"
16 March 2009
Orion files suit blocking Wockhardt's generic Stalevo
26 January 2009
Azur buys four drugs from UCB
19 January 2009
Wockhardt seeks to make generic of Orion's Stalevo in USA
15 December 2008
FDA clears two new strengths of Novartis' Stalevo
3 November 2008
Mylan's generic Parcopa gets FDA OK
29 September 2008
UK's MHRA clears Chelsea's droxidopa Ph II study
4 August 2008
Orion seek broader indication for Stalevo
21 April 2008
FDA says IMPAX' Vadova not approvabale
4 February 2008
Orion/Novartis' Stalevo fares well in Ph III trial
4 February 2008
Higher dose of Novartis' Stalveo cleared in USA
13 August 2007
13 new drugs added to Japan's NHI list
19 March 2007
FDA issues non-appro letter for IMPAX' Vadova
13 March 2006
Orion Pharma sees 37% hike in 2005 profits
20 February 2006
Mylan sees 12% drop in fourth-qtr profit
23 May 2005
Australian PBS new Rx listings aimed at seniors
11 April 2005
Mylan's 3rd-qtr revenues slump 17%
14 February 2005
GB Thera acquires Ph III PD agent from Chiesi
7 February 2005
Valeant moves closer to Zelapar approval
17 January 2005
Orion sees sales fall for first nine months
15 November 2004
Mylan sees sales drop 15% for 2nd qtr
8 November 2004
KV resolves a handful of legal matters
20 September 2004
Trial to assess Stalevo in delaying dyskinesia
13 September 2004
FDA approves Schwarz Pharma's Parcopa
13 September 2004
Orion/Abbott expand levosimendan accord
26 April 2004
EU clears Orion/Novartis' Stalevo
3 November 2003
Orion and Novartis' Stalevo shows benefits in Parkinson's disease
8 September 2003
Orion's PD therapy is approved by FDA
30 June 2003
India acts on prices of 87 drug formulations
9 June 2003
Italy's Chiesi sees flat sales in 2002
28 April 2003
Merck backs off Impax lawsuit?
14 April 2003
Chiesi of Italy sets out expansion plans for rest of Europe
29 November 2001
Sanofi-Synthelabo to buy out Indian JV
30 May 2001
Overseas sales boost Orion Pharma
10 November 2000
Orion to develop combo Parkinson's drug
7 September 2000
Indian NPPA imposes drug price changes
23 May 2000
Roche And DuPont In Parkinson's Link-Up
6 August 1998
Chiesi Aims For Top 20 Place In Italian Market
5 August 1998
Forecasts For Global CNS Growth
23 June 1998
Euro CPMP April Plenary Meeting
18 June 1998
Parkinson's Patch Enters Phase II
25 November 1996
Sandoz To License Orion Parkinson's Drug
4 March 1996
P&U Files In USA For Parkinson's Drug
15 January 1996
Novel Drugs Will Drive Euro Anti-Parkinson's Market
27 November 1995
WEST POINT EXPANDS PRODUCT LINE
9 May 1994
DUPONT MERCK TO PROMOTE LAMICTAL
16 August 1993
THREE-WAY GENERIC AGREEMENT
31 May 1993
NEW APPROACHES IN TREATING PARKINSONISM
7 December 1992
TEVA AND DU PONT MERCK SALES DEAL
12 October 1992
Showing 1-61 of 61 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
